ImmunologybioRxiv
MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition
L. Vande Walle, I. B. Stowe, P. Sacha…·M. Lamkanfi
This study identifies the NACHT domain of wildtype NLRP3 as the target of MCC950/CRID3, showing it inhibits inflammasome activity but not CAPS-associated mutants.
DOI 10.1371/journal.pbio.3000354